The DLBCL90 gene-expression assay identifies double-hit lymphomas with high sensitivity in patients from two phase II clinical trials with high-risk diffuse large B-cell lymphoma

EJHaem. 2020 Dec 5;2(1):104-108. doi: 10.1002/jha2.109. eCollection 2021 Feb.

Kathrine T Isaksen^{1

2

3}, Klaus Beiske^{3

4}, Erlend B Smeland^{1

2}, Judit Jørgensen⁵, Marianne Brodtkorb^{1

2}, June Helen Myklebust^{1

2}, Mats Jerkeman⁶, Leo Meriranta^{7

8}, Marja-Liisa Karjalainen-Lindsberg⁹, Sirpa Leppä^{7

8}, David W Scott¹⁰, Harald Holte^{2

11}, Yngvild Nuvin Blaker^{1

2

3}

¹ Department of Cancer Immunology Institute for Cancer Research Oslo University Hospital Oslo Norway.
² KG Jebsen Centre for B cell malignancies University of Oslo Oslo Norway.
³ Institute of Clinical Medicine University of Oslo Oslo Norway.
⁴ Department of Pathology Oslo University Hospital Oslo Norway.
⁵ Department of Hematology Aarhus University Hospital Aarhus Denmark.
⁶ Department of Oncology Lund University and Skåne University Hospital Lund Sweden.
⁷ Helsinki University Hospital Comprehensive Cancer Centre and University of Helsinki Helsinki Finland.
⁸ iCAN Digital Precision Cancer Medicine Flagship Helsinki Finland.
⁹ Department of Pathology Helsinki University Hospital Helsinki Finland.
¹⁰ Centre for Lymphoid Cancer British Columbia Cancer Vancouver Canada.
¹¹ Department of Oncology Oslo University Hospital Oslo Norway.

No abstract available